Back to top anchor

Discovery improves potency and safety of cancer-killing immunotherapy treatment

CAR T cell therapy1 is a revolutionary treatment that uses cells from a patient’s own immune system to fight cancer. A patient’s immune cells (T cells) are reprogrammed to directly identify and attack cancer cells. The modified T cells are then returned to the patient where they attack and destroy cancer cells.

Professor Alex McLellan

CAR T cell therapy is normally given to patients who have hard-to-treat and/or resistant cancer. While it is currently FDA-approved for treating some blood cancers, including multiple myeloma, solid cancer tumours have proven much harder to treat.

Through work funded by a Health Research Council (HRC) Project Grant, a team of University of Otago researchers led by Professor Alexander McLellan (pictured) discovered that a new combination of cell types significantly improved monotherapy of CAR T cells against a range of blood and solid cancers. They also found a way to control their activity to prolong the cellular battle against cancer.

Solid tumours remain a major challenge for cellular immunotherapy, and CAR T cells used as a single-agent approach have shown limited effectiveness in these settings.

“There are major barriers to treating solid cancers with cellular therapy. Both malignant cells and supporting host cells form a suppressive barrier that inhibits the infiltration and activity of the immune cells,” says Professor McLellan.

Another problem is the difference in target antigen expression between individual solid tumour cells.

“Some tumour cells lose expression of the chosen target antigen and will escape a specific monotherapy.”

“We discovered that a subset of cells called natural killer (NK) cells, which we knew helped T cells from our previous work, could also help CAR T cells to overcome these barriers.”

“Our process allows for the cost-effective expansion of NK cells from a normally discarded product during CAR T cell manufacture. The NK cells can be engineered with a distinct CAR to further help prevent cancer cells from escaping from the target antigen.”

Professor McLellan says NK cells are very safe and don’t cause graft-versus-host disease even when they come from an unrelated donor. This feature gives them great potential to be combined with CAR T cells. 

Although CAR T cell therapy has produced some wonderful outcomes for cancer patients who can access the treatment, Professor McLellan says there are still patients whose cancer returns.

“We believe our combination CAR T and NK cell therapy could improve the relapse rate and expand into solid cancers because it re-energises the CAR T cells and makes them work harder. Every cancer we’ve treated in a pre-clinical model so far – leukaemia, lymphoma, multiple myeloma and breast cancer – has responded significantly better to this combination therapy.”

The team also discovered that putting the CAR under the control of a natural T cell gene promoter allowed the engineered T cells to switch from idle to active only when needed.

“This rheostat system allows us to genetically control the CAR T cells and put them to ‘idle mode’ when they are not in contact with cancer cells. This means the CAR T cells don’t wear themselves out or reprogramme into unhelpful tired cells.”

Professor McLellan says the next step towards clinical trials application is to get their unique products licensed for public use in New Zealand.

1 CAR T cell therapy stands for Chimeric Antigen Receptor T cell therapy.